Biopharmaceutical and Biomedicine Market Size & Share to Exceed USD 1803.2 Billion by 2034, at CAGR of 12.20%. “Harnessing the Power of Genomics for Precision Medicine"– By PMI
February 12, 2024 19:30 ET
|
PMI
Covina, Feb. 12, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Biopharmaceutical and Biomedicine Market size was valued at about USD 570.0 Billion in 2024 and expected to...
Sermonix Pharmaceuticals Shares Pharmacokinetic and Baseline Genomic Clinical Data Tied to ELAINE Lasofoxifene Trials of Patients With ESR1 Mutations
December 12, 2023 09:00 ET
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
Axial Spondyloarthritis Market Awareness Campaigns Promote Early Diagnosis and Improved Outcomes – By PMI
October 17, 2023 13:30 ET
|
PMI
Covina, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Axial Spondyloarthritis affects joints in axial skeleton such as chest, pelvis and spine. Skin and nail changes of Psoriasis, longstanding low back pain,...
Biopharmaceuticals Market Revenues to Reach USD 704.91 billion by 2028 - Market Size, Share, Forecasts, & Trends Analysis Report by Mordor Intelligence
July 27, 2023 09:30 ET
|
Mordor Intelligence
Hyderabad, July 27, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled “ Biopharmaceuticals Market Report (2023-2028),” the market is estimated at USD 478.20 billion in 2023....
Insulin Market Revenues to Reach USD 32.55 billion by 2028 - Market Size, Share, Forecasts, & Trends Analysis Report by Mordor Intelligence
July 03, 2023 09:30 ET
|
Mordor Intelligence
Hyderabad, July 03, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled "Insulin Market Report (2023-2028)," the market is estimated at USD 26.92 billion in 2023. It is...
Sermonix Pharmaceuticals to Share Longer Patient Follow-up Results for ELAINE-2 in Poster Presentation at ASCO 2023
May 25, 2023 17:00 ET
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, May 25, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
Global High Potency APIs Market to Reach $41.4 Billion by 2031: Allied Market Research
November 25, 2022 05:17 ET
|
Allied Market Research
Portland, OR, Nov. 25, 2022 (GLOBE NEWSWIRE) -- A new business intelligence report released by Allied Market Research, the global High Potency APIs Market generated $19.7 billion in 2021, and is...
Global Joint Pain Injections Market is Expected to Generate $13.2 Billion by 2031: Allied Market Research
November 15, 2022 02:35 ET
|
Allied Market Research
Portland, OR, Nov. 15, 2022 (GLOBE NEWSWIRE) -- A new business intelligence report released by Allied Market Research, the global Joint Pain Injections Market size garnered $6.3 billion in 2021, and...
Sermonix to Present Updated Data from ELAINE-2 Clinical Trial of Lasofoxifene in Combination with Abemaciclib in Women with Locally Advanced or Metastatic ER+/HER2− Breast Cancer and an ESR1 Mutation after Progression on Prior Therapies at the 2022 ASCO Annual Meeting
May 31, 2022 15:25 ET
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, May 31, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated...
Sermonix Pharmaceuticals Completes Enrollment of Phase 2 Clinical Trial Collaboration Studying Lasofoxifene in Combination With Eli Lilly and Company’s Abemaciclib
June 28, 2021 10:13 ET
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, June 28, 2021 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to treat ESR1-mutated metastatic breast...